Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

Overview

• US life sciences technology firm's Q3 revenue rose, beating analyst expectations

• Adjusted EPS for Q3 grew 21% and beat analyst expectations

• Company acquired MOBILion Systems to expand mass spectrometry capabilities

Outlook

• Waters raises full-year 2026 total revenue guidance to $6.479 bln-$6.497 bln

• Company lifts full-year 2026 adjusted EPS outlook to $14.60-$14.70

• Waters expects Q4 2026 revenue of $1.801 bln-$1.819 bln and adjusted EPS of $4.58-$4.68

Result Drivers

• CONSUMABLES AND INSTRUMENTS - Co said double-digit growth in instrument and chemistry consumables sales in Analytical Sciences Division was driven by new product innovation, strong execution, and higher customer testing volume

• REAGENT SALES - Biosciences Division saw high single-digit growth in reagents, with both research and clinical reagents contributing, reflecting a 400bps acceleration in year-over-year growth

• INSTRUMENT REPLACEMENT AND SPECIALTY DEMAND - LC-MS instrument growth was driven by robust replacement trends and demand related to GLP-1s, PFAS, and India generics, per CEO

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Waters Corp is $470.00, about 4.6% above its November 2 closing price of $449.53

• The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago

Reuters Recommended Reads

• Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

• Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

• Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)